Australia's largest stock trading and investment forum Australia's #1 stock forum

RAP

Click for more information

0.00%

20.5¢ resapp health limited

Ann: RAP Licenses Additional Pneumonia Diagnostic from UniQuest, page-159

First 159 Last

Share
Profile

Follow
shaunstewart1

168 Posts.

21

03/05/17

15:34

Post #: 24443907
Share

Originally posted by shaunstewart1 ↑

I agree with your analysis CT,

I think one thing holding them back from establishing deals with Telehealth partners embedded with the clause 'subject to FDA approval' is because they cannot actually market without FDA approval?

From the De Novo Guidance:

If the submitter demonstrates that the criteria at section 513(a)(1)(A) or (B) of the FD&C Act 101 are met, we will grant the de novo, in which case the specific device and device type is 102 classified in class I or class II. The device may then be marketed immediately
(bold my own)

Expand

...If the de novo is declined, the device remains in class III and may not be marketed.

https://www.fda.gov/downloads/Medic...onandGuidance/GuidanceDocuments/UCM273903.pdf
page 5 section 3

Last edited by shaunstewart1: 03/05/17

RAP Price at posting: 31.0¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

PYC

PYC commences new study on drug for eye condition Retinitis Pigmentosa type 11

AZY

Antipa's Minyari Dome reveals gold up to 24g/t through drilling at key prospect

MM1

Midas logs 17 spodumene pegmatite targets over 4km at Aylmer Project in Canada but drills while off

OCC

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

SRL

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

There are more pages in this discussion • 48 more messages in this thread...

First 159 Last

Add RAP (ASX) to my watchlist

SPONSORED BY